Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 23, 2009New England Journal of MedicineOpen Access

High-Dose Daunorubicin in Older Patients with Acute Myeloid Leukemia

View Full Paper
Ask AI
Bookmark
Share

Authors

Bob LöwenbergBob LöwenbergNorthwestern UniversityGOGert J. OssenkoppeleDutch Cancer SocietyWPWim van PuttenUniversity of California, San Francisco

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Löwenberg et al. (2009) studied this question.

synapsesocial.com/papers/6a0823851e0fcf4a43e8aabdhttps://doi.org/10.1056/nejmoa0901409
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Full dose versus attenuated dose daunorubicin, cytosine arabinoside, and 6-thioguanine in the treatment of acute nonlymphocytic leukemia in the elderly.1984 · 146 citations
  2. 2Various distinctive cytogenetic abnormalities in patients with acute myeloid leukaemia aged 60 years and older express adverse prognostic value: results from a prospective clinical trial2006 · 69 citations
  3. 3Acute Myeloid Leukemia and Myelodysplastic Syndromes in Older Patients2007 · 234 citations
  4. 4Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy--the value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: final report. European Organization for the Research and Treatment of Cancer and the Dutch-Belgian Hemato-Oncology Cooperative Hovon Group.1998 · 288 citations
  5. 5Prognostic factor analysis of the survival of elderly patients with AML in the MRC AML11 and LRF AML14 trials2009 · 239 citations